Monomil XL 60mg SSP059: For Those Prescription Change Requests

General Practice professionals will be please to learn that the Department of Health and Social Care has introduced a Serious Shortage Protocol for Momonil XL 60mg Modified Release Tablets. This remains valid over the period 26 March 2024 to 03 May 2024. SSP056 allows pharmacies to supply alternatives in the following order, with Group 1 in preference to Group 2:

Group 1

Isosorbide mononitrate (Chemydur® 60XL) 60mg modified-release tablet
OR
Isosorbide mononitrate (Relosorb® XL) 60mg modified-release tablet
OR
Isosorbide mononitrate (Isotard® 60XL) 60mg modified-release tablet

Group 2

Isosorbide mononitrate (Monomax® XL) 60mg modified-release tablet
OR
Isosorbide mononitrate (Monosorb® XL 60) 60mg modified-release tablet
OR
Isosorbide mononitrate (Tardisc®XL 60) 60mg modified-release tablet

Note that the protocol applies to all NHS and private prescriptions. It also does not allow for the quantity supplied to be less than the number of days prescribed on the original prescription. It will remain effective from 26 March 2024 to 03 March 2024.

Cautions

• Patients should be made aware of the change and be warned of possible adverse events that they may experience particularly in the first few days. The most important is hypotension (low blood pressure) as well as faster heart rate. Also, headache may get worse. If they have concerns, they should contact their doctor.

• Pharmacies must ensure that patients considered unsuitable for inclusion are promptly referred to their prescriber for further advice.

Exclusion Criteria

• The patient presents with a prescription for a medicine other than isosorbide mononitrate (Monomil® XL) 60mg modified release tablets.
• The patient presents a prescription which is not valid.
• The patient/carer does not consent to receiving the medicine(s) supplied under this SSP.
• Where the pharmacist, using their professional judgement, determines that the patient is not suitable to receive alternative medicine under this SSP.
• Known previous hypersensitivity or severe adverse reaction to one of the alternative tablets allowed in accordance with this protocol, or their excipients.
• Patients aged less than 18 years.

Further details of the SSP are available here.

If you haven’t subscribed to updates from the GP Pharmacy Club yet, why not consider doing so here?